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To the Editor: 
 
The study from Bajaj and colleagues – evaluating gut microbiome-metabonome changes in cirrhotic 
patients receiving fecal microbiota transplant (FMT)1 – merits further discussion of its conclusions. 
 
In this study, cirrhotic patients with hepatic encephalopathy (HE) taking standard of care (SOC) therapy 
were randomised to either continue with SOC alone, or to also receive five days of antibiotics prior to 
a single FMT enema.  The investigators demonstrate partial recovery of microbiota, bile acid, and 
short-chain fatty acid (SCFA) profiles for patients in the FMT arm, and conclude that FMT directly 
restores gut microbiome-metabonome interactions in antibiotic-treated cirrhotics1.  However, there 
was no arm in this study where patients received antibiotics but no FMT; therefore, it is impossible to 
distinguish whether any changes observed were directly caused by FMT as claimed, or at least partly 
represent purely gut microbiota recovery after completion of antibiotics. 
 
There are certainly grounds for questioning the efficacy of the FMT.  Specifically, despite selecting a 
stool donor with high relative abundance of Lachnospiraceae and Ruminococcaceae, FMT recipients 
actually demonstrate a significantly reduced relative abundance of these bacterial families post-FMT 
(day 20) compared to baseline values (day 0) (Figure 21).  Furthermore, it is well-established that 
human gut microbiota structure recovers to a profile comparable to that found pre-antibiotics within 
a short period following completion of an antibiotic course2.  Additionally, whilst poorly-explored in 
cirrhosis, SCFA3 and bile acid profiles4 reconstitute over a time course of days to weeks after antibiotic 
cessation in healthy rodents without any specific intervention.   
 
If FMT directly treated HE through modulation of gut microbiota-metabonome interactions, then it 
would be expected that at least some of these variables would exceed baseline values post-FMT, 
rather than only match baseline levels at best, as shown.  Adverse events associated with FMT are 
uncommon, but serious adverse events are described – including bacteraemia – in the non-cirrhotic 
population5; such concerns are clearly amplified in decompensated cirrhotics, giveŶ this group’s 
propensity to and outcomes from sepsis.  Until the safety profile of FMT within cirrhotic patients has 
been further evaluated – and a potential mechanistic link between FMT and improvement in HE 
defined - then FMT remains at too early a stage to consider more widely as HE treatment. 
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